Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Clinical trial NCT04003610 · TERMINATED

Trial details

NCT number: NCT04003610
Sponsor: Incyte Corporation
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Urothelial Carcinoma Unresectable Urothelial Carcinoma

Start date: 2020-05-14
Primary completion: 2021-04-18
Enrollment: 7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.